Osimertinib and Bevacizumab Cotreatment for Untreated EGFR-Mutated NSCLC With Malignant Pleural or Pericardial Effusion (SPIRAL II): A Single-Arm, Open-Label, Phase 2 Clinical Trial-Reference-Cited by-同舟云学术

Osimertinib and Bevacizumab Cotreatment for Untreated EGFR-Mutated NSCLC With Malignant Pleural or Pericardial Effusion (SPIRAL II): A Single-Arm, Open-Label, Phase 2 Clinical Trial

Published:2022-12 Issue:12 Volume:3 Page:100424
ISSN:2666-3643
Container-title:JTO Clinical and Research Reports
language:en
Short-container-title:JTO Clinical and Research Reports

Author:

Hibino Makoto,Hiranuma Osamu,Takemura Yoshizumi,Katayama Yuki,Chihara Yusuke,Harada Taishi,Fujita Kohei,Kita Toshiyuki,Tamiya Nobuyo,Tsuda Takeshi,Shiotsu Shinsuke,Tamura Yukihiro,Aoyama Takashi,Nakamura Yoichi,Terashima Masaaki,Morimoto Yoshie,Nagata Kazuhiro,Yoshimura Kenichi,Uchino Junji,Takayama Koichi

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference45 articles.

1. Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update;Bethune;J Thorac Dis,2010

2. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy;Keedy;J Clin Oncol,2011

3. EGFR mutation testing on cytological and histological samples in non-small cell lung cancer: A Polish, single institution study and systematic review of European incidence;Szumera-Ciećkiewicz;Int J Clin Exp Pathol,2013

4. EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples;Ellison;J Clin Pathol,2013

5. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study;Douillard;Br J Cancer,2014

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Malignant pleural effusion diagnosis and therapy;Open Life Sciences;2023-01-01